Mogamulizumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | CCR4 |
| Clinical data | |
| Pronunciation | moe gam" ue liz' ue mab |
| Trade names | Poteligeo |
| Other names | mogamulizumab-kpkc |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a618064 |
| License data | |
| Pregnancy category | |
| Routes of administration | Intravenous |
| Drug class | Antineoplastic agent |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6520H10072N1736O2020S42 |
| Molar mass | 146444.95 g·mol−1 |
| (what is this?) (verify) | |
Mogamulizumab, sold under the brand name Poteligeo, is a humanized, afucosylated monoclonal antibody targeting CC chemokine receptor type 4 (CCR4).[5][7] It is given by injection into a vein.[5][6]
The most common side effects include rash, infusion-related reactions, fatigue, diarrhea, musculoskeletal pain, and upper respiratory tract infection.[8]
Mogamulizumab was approved for medical use in Japan in 2012. It was approved for medical use in the United States and the European Union in 2018.[5][6] It was approved for medical use in Canada in 2022. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.[9]
- ^ a b "Poteligeo". Therapeutic Goods Administration (TGA). 15 February 2021. Archived from the original on 9 September 2021. Retrieved 8 September 2021.
- ^ a b "AusPAR: Mogamulizumab". Therapeutic Goods Administration (TGA). 10 May 2021. Archived from the original on 9 September 2021. Retrieved 8 September 2021.
- ^ "Poteligeo Product information". Health Canada. 25 April 2012. Archived from the original on 1 October 2022. Retrieved 30 September 2022.
- ^ "Summary Basis of Decision - Poteligeo". Health Canada. 23 October 2014. Archived from the original on 28 November 2022. Retrieved 28 November 2022.
- ^ a b c d "Poteligeo- mogamulizumab-kpkc injection". DailyMed. 27 April 2023. Retrieved 15 May 2024.
- ^ a b c "Poteligeo EPAR". European Medicines Agency (EMA). 14 October 2016. Archived from the original on 5 July 2021. Retrieved 15 May 2024.
- ^ Yu X, Marshall MJ, Cragg MS, Crispin M (June 2017). "Improving Antibody-Based Cancer Therapeutics Through Glycan Engineering" (PDF). BioDrugs. 31 (3): 151–166. doi:10.1007/s40259-017-0223-8. PMID 28466278. S2CID 3722081. Archived (PDF) from the original on 26 August 2021. Retrieved 15 May 2024.
- ^ Cite error: The named reference
FDA PR 20180808was invoked but never defined (see the help page). - ^ New Drug Therapy Approvals 2018. U.S. Food and Drug Administration (FDA) (Report). January 2019. Archived from the original (PDF) on 17 September 2020. Retrieved 16 September 2020.